Adagrasib is a targeted therapy for KRAS G12C mutations, which has attracted much attention in the field of non-small cell lung cancer in recent years. This article will systematically analyze the core information of the drug from three dimensions: price, indications and therapeutic effects, and provide practical reference for patients and medical practitioners.
How much is Adagrasib?
The global market price of Adagrasib varies significantly, mainly affected by manufacturers and regional policies. Different versions of pricing strategies are directly related to the patient's economic burden and medication selection.
Comparison of prices of original drugs and generic drugs
The original drugs produced by Mirati in the United States are divided into two specifications: the reference price of the US domestic version of 200mg*180 tablets is US$28,832, and the price of the same specification of the export Hong Kong version has risen to about US$33,401. The generic drug produced by Lucius in Laos is 200mg*90 tablets, priced at about US$822 per box, and the price is for reference only.
Drug purchasing channels and cost optimization
Since Adagrasib has not yet been launched in China and is not included in medical insurance, patients need to obtain it through cross-border medical platforms or overseas direct mail. When purchasing, the source of the drug must be strictly verified and the risk of counterfeit drugs must be guarded. For patients with greater financial pressure, Lao generic drugs can be an alternative, but they need to weigh the efficacy and safety under the guidance of a doctor.
The price difference reflects the balance between market supply and demand and production costs. Patients need to choose a suitable medication plan based on their own situation.
Indications for Adagrasib
The clinical application of Adagrasib is strictly limited to people with specific gene mutations, and its range of indications reflects the core principles of precision medicine.
Genetic testing requirements for applicable populations
The drug is only suitable for adult patients with KRAS G12C mutations confirmed by FDA-approved testing. The incidence of this mutation in non-small cell lung cancer is about 13%, and patients need to confirm the mutation status through tissue biopsy or liquid biopsy before starting treatment.
Treatment stage and combination drug restrictions
According to the US FDA approval, patients must have locally advanced or metastatic non-small cell lung cancer that has progressed after at least one systemic treatment. For patients with congenital long QT syndrome or abnormal liver function, the risk of medication should be strictly evaluated.
The precise definition of indications not only maintains the effectiveness of treatment, but also provides a clear biological basis for clinical decision-making.
The therapeutic effect of Adagrasib
It is a breakthrough drug in the field of KRAS inhibitors. Adalagracib shows unique advantages and challenges in efficacy and safety.
Targeted effect and clinical response rate
By irreversibly binding to KRAS G12C protein, the drug can block the tumor cell proliferation signaling pathway. Clinical trials have shown that the objective response rate of monotherapy is 43%, and the median progression-free survival is 6.5 months, which significantly prolongs the patient's survival.
Monitoring and management of adverse reactions
During the treatment process, it is necessary to focus on serious adverse reactions such as hepatotoxicity, QT interval prolongation and interstitial lung disease. More than 25% of patients experience gastrointestinal reactions, which need to be controlled through preventive medication and dose adjustment. Regular monitoring of electrocardiograms, liver enzyme indicators and lung imaging changes are the core measures of risk management.
The dynamic balance between efficacy and risk requires doctors and patients to establish a close monitoring and collaboration mechanism to maximize the benefits of treatment.
